Clinical trials

Vaccine
#BioNTech #Cancer vaccine #Clinical trials #mRNA #Oncology #UK

NHS England launches country-wide cancer vaccine trials

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments. The vaccines being jointly developed by biopharmaceutical companies BioNTech and Genentech are… Read More

#Cancer Research #News #Trending News

Human heart
#Clinical trials #Drug discovery #Heart failure

Heart failure drug to progress to Phase II trials

Cytokinetics has announced topline data from the Phase I study of cardiac myosin inhibitor CK-4021586 (CK-586), which met its primary and secondary objectives.   The data support the advancement of CK-586 to a Phase II clinical trial in patients with heart failure with preserved ejection fraction (HFpEF) which… Read More

#News

Diversity
#Clinical trial design #Clinical trials #Diversity #University of Oxford

Deterrents to trial participation among ethnic minorities revealed

Safety and health concerns, time investment, and lack of support are the top three barriers to participation in clinical studies among ethnic minorities, according to a new report. The study examined the motivators and deterrents of clinical trial participation among ethnic minorities and outlined strategies sponsors can utilise… Read More

#News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  A leading news story this week has been the announcement of positive Phase II… Read More

#News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

This week in drug discovery (6-10 May) 

News round-up for 6-10 May by DDW Multimedia Editor Megan Thomas. A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the… Read More

#News

#Clinical trials #Concussion #Drug discovery #Neuroscience

Q&A: Developments in concussion therapies

DDW Editor Reece Armstrong speaks to Michael Wyand, Chief Executive Officer/Director, Oxeia Biopharmaceuticals about the development of the company’s treatment for concussion (OXE103) and the current lack of effective therapies for brain injuries.   RA: Tell us how OXE103 works?   MW: OXE103 (ghrelin) is a 28 amino acid neuro-peptide hormone… Read More

#Exclusive Content

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Calliditas Therapeutics #Cancer research #Clinical trials #Head and neck cancer #Squamous cell carcinoma

Positive results of Phase II head and neck cancer trial 

Calliditas Therapeutics has announced data from the proof-of-concept Phase II trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN).  The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in… Read More

#News

#Artificial intelligence (AI) #Clinical trial design #Clinical trials #Machine learning

AI and machine learning: A new era for clinical trials

Fiona Maini, Senior Director Global Compliance & Strategy, at Medidata looks at the rise of artificial intelligence (AI) and machine learning (ML) within life sciences and the applications for the technology in clinical trials. The benefits that AI and machine learning (ML) can bring to society and their potential to… Read More

#Exclusive Content #Trends & Analysis

Vaping smoking cessation
#Clinical trials #Plant-based #Smoking cessation #Vaping

Plant-based drug can help people quit vaping, study shows 

A plant-based medication called cytisinicline may be an effective therapy to people stop vaping, according to the ORCA-V1 trial results in the Journal of the American Medical Association (JAMA) Internal Medicine.   Cytisinicline, also known as cytisine, baptitoxine, or sophorine, is an alkaloid that occurs naturally in… Read More

#News

#Clinical trials #FDA

FDA fast tracks Amolyt’s hypoparathyroidism therapy  

Amolyt Pharma has announced that its lead therapeutic peptide candidate, eneboparatide, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).  The company’s lead therapeutic peptide candidate is currently in a Phase III clinical trial for the treatment of hypoparathyroidism.  Hypoparathyroidism… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

Seed fund
#Clinical trials #Drug discovery #Financing

$75m in funding to develop tenosynovial giant cell tumour mAb 

SynOx Therapeutics has closed a $75m Series B financing round, which will be used to generate registrational Phase III clinical and CMC data for emactuzumab, the company’s potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of tenosynovial giant cell tumour (TGCT).  TGCT is a type… Read More

#News

Woman using mobile phone
#Charity #Clinical trials #Myeloma

New search tool to help myeloma patients find clinical trials

Myeloma Patients Europe (MPE) has launched a new online tool to facilitate the search of clinical trials in myeloma. The Myeloma and AL Amyloidosis European Clinical Trial Navigator is designed to help patients find clinical trials for myeloma, monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

New DDW Highlights podcast: 22 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week all concerns clinical trials for new drugs that could… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

This week in drug discovery (15-19 April) 

News round-up for 15-19 April by DDW Digital Content Editor Diana Spencer. The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. Read More

#News